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Fatty Acid Transport Protein-2 inhibitor Grassofermata/CB5 
protects cells against lipid accumulation and toxicity
Nipun Saini, Paul N. Black, David Montefusco, and Concetta C. DiRusso*
Department of Biochemistry, University of Nebraska-Lincoln, Lincoln, NE 68588
Abstract
The inhibition of the fatty acid uptake into non-adipose tissues provides an attractive target for 
prevention of lipotoxicity leading to obesity-associated non-alcoholic fatty liver disease and type 2 
diabetes. Fatty acid transport proteins (FATPs) are bifunctional proteins involved in the uptake 
and activation of fatty acids by esterification with coenzyme A. Here we characterize 
Grassofermata/CB5, previously identified as a fatty acid uptake inhibitor directed against 
HsFATP2. The compound was effective in inhibiting the uptake of fatty acids in the low micro-
molar range (IC50 8–11μM) and prevented palmitate-mediated lipid accumulation and cell death in 
cell lines that are models for intestines, liver, muscle and pancreas. In adipocytes, uptake 
inhibition was less effective (IC50 58μM). Inhibition was specific for long chain fatty acids and 
was ineffective toward medium chain fatty acids, which are transported by diffusion. Kinetic 
analysis of Grassofermata-dependent FA transport inhibition verified a non-competitive 
mechanism. By comparison with Grassofermata, several atypical antipsychotic drugs previously 
implicated as inhibitors of FA uptake were ineffectual. In mice Grassofermata decreased 
absorption of 13C-oleate demonstrating its potential as a therapeutic agent.
Keywords
Fatty acid transport; FATP2 inhibitor; lipotoxicity; atypical antipsychotics
1. Introduction
Chronically elevated levels of fatty acids (FA) in systemic circulation are considered major 
contributing factors to the development of disease states including obesity, type 2 diabetes 
and non-alcoholic fatty liver disease (NAFLD). The over-accumulation of free fatty acids in 
cells results in cellular dysfunction and organ failure by a process called lipotoxicity that 
leads to programmed cell death or lipoapoptosis [1,2,3]. Fatty acids are imported from blood 
against a concentration gradient by protein-mediated transport that is coupled to activation 
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with coenzyme A in a process called vectorial acylation [4]. FA uptake is mediated by a 
subset of members of the Fatty Acid Transport Protein family (FATP; SLC27A)[5]. In 
previous work, we selected inhibitors of human FATP2 using a novel high throughput 
screening approach that targeted FA transport specifically [6]. This led to the identification 
of 2-benzyl-3-(4-chlorophenyl)-5-(4-nitrophenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one then 
designated CB5 now called Grassofermata. Grassofermata was shown to be capable of 
inhibiting the uptake of FA-analog C1-BODIPY-C12 using a live cell based assay in yeast as 
well as mammalian cell lines that are models for liver, small intestines and adipose tissue 
[6,7]. The atypical antipsychotic (AAP) drugs clozapine and chlorpromazine that are 
structurally related to phenothiazines, were also identified as inhibitors of FA uptake [8]. 
The latter compounds demonstrated intermediate levels of inhibition of C1-BODIPY-C12 
uptake at 80μM in yeast expressing HsFATP2. Thus it was hypothesized that dyslipidemia 
caused by these antipsychotics is due to inhibition of FA uptake through a FATP.
In the current study, we have further characterized Grassofermata for its activity as an 
inhibitor of FA uptake in various cell lines that are models for pancreatic islets, muscles and 
human adipocytes; its specificity for long and very long chain fatty acid; and its protective 
effects against the saturated fatty acid palmitic acid (PA). Grassofermata was also 
administered to mice demonstrating its ability to limit FA absorption in vivo. Finally, we 
demonstrate that the antipsychotics are not specific inhibitors of FA transport and therefore, 
their mechanism of action in causing dyslipidemias does not involve the FATPs.
2. Materials and methods
2.1 Materials
Grassofermata (2-benzyl-3-(4-chlorophenyl)-5-(4-nitrophenyl)pyrazolo[1,5-
a]pyrimidin-7(4H)-one) was purchased from ChemBridge Corporation (San Diego, CA, 
USA). Fluorescent fatty acid analogs C1-BODIPY 500/510-C12 (D-3823), BODIPY-FL-C5 
(D-3834) and BODIPY-FL-C16 (D-3821) were purchased from Molecular Probes® (Life 
Technologies, Inc. Grand Island, NY). Antipsychotic drugs Haloperidol, Clozapine and 
Risperidone; 13C labeled oleic acid; tyloxapol and palmitic acid (PA) were purchased from 
Sigma Aldrich (St. Louis, MO). Olanzapine (O253750) was purchased from Toronto 
Research Chemicals (Toronto, ON) and Quetiapine from Key Organics/BIONET (Bedford, 
MA). Orlistat, was a gift of GlaxoSmithKline (Philadelphia, PA). Fatty acid-, nuclease-, and 
protease-free Bovine Serum Albumin (BSA) was purchased from CalBiochem (San Diego, 
CA).
2.2 Cell culture and reagents
HepG2 cells and Caco2 cells were cultured as previously described [6]. INS-1E cells 
(generously provided by Pierre Maechler, Ph.D., University Medical Center of Geneva 4, 
Switzerland) were cultured at 37 °C 5 % CO2 in complete medium composed of RPMI 1640 
(Thermo Fisher Scientific, Inc., Waltham, MA) supplemented with 5 % FBS, 1mM sodium 
pyruvate, 50 μM, 2-mercaptoethanol and 10 mM HEPES as described [9]. The cells were 
seeded in 96-well collagen coated black/clear plate at a density of 2x105 cells/well and used 
for experimentation after 96 hours. C2C12 cells (ATCC, Manassas, VA) were maintained in 
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Dulbecco modified Eagle medium (DMEM) containing 10 % FBS and 2 mM of L-
glutamine at 37 °C and 5 % CO2. For differentiation, cells were plated in differentiation 
medium (DMEM containing 10 % horse serum) at a density of 8x104 cells/well on a black/
clear 96-well plate for 96 hours.
De-identified human adipocytes (generously provided by Susan K. Fried, Ph.D., Boston 
University) were seeded in 96-well black/clear plates at a density of 1.5x104 cells/well and 
then maintained in propagation media containing modified MEM, Alpha Modification, with 
L-Glutamine, Ribo/Deoxyribonucleosides (HyClone) and 10 % FBS. For differentiation into 
adipocytes, cells were treated with differentiation media supplemented with 540 μM IBMX 
and 1 μM rosiglitazone for 6 days. The media was then changed to differentiation media 
without IBMX and rosiglitazone until lipid droplets were obvious upon microscopic 
examination.
Primary hepatocytes were isolated from 129S1/SvImJ (002448, Jackson laboratory) wild 
type mice (10–12 weeks) as described [10]. Prior to sacrifice animals were housed in the 
AAALAC approved facility at the University of Nebraska – Lincoln (UNL) in ventilated 
cages at 22 °C with a 14/10 hour day/night cycle and were allowed free access to water and 
standard laboratory chow (2016 Teklad Global 16 % Protein Rodent Diet (Harlan 
Laboratories)). All animal studies were reviewed and approved by the Institutional Animal 
Care and Use Committee of UNL. After isolation, hepatocytes were re-suspended in growth 
media containing DMEM-High glucose, 10 % FBS, Penicillin/streptomycin, Glucagon (14 
ng/ml), Hydrocortisone (7.5 μg/ml), EGF (20 ng/ml) and Insulin (0.5 U/ml) and then plated 
in a 96-well collagen coated plates at a density of 1.5x104 cells/well. After 4–5 hours of 
attachment, the media was replaced with fresh growth media and cells used within 24 hours 
for experimentation.
2.3 Evaluation of fatty acid uptake inhibition
FA uptake inhibition was measured using the fluorescent fatty acid analogue C1-BODIPY-
C12 as detailed [11]. Cell-associated fluorescence was measured using a BioTek Synergy 
plate reader (Gen5.2 software) at an excitation/emission of 485/528nm. The data was 
analyzed by non-linear regression using one-site competition and dose response models in 
Prism software (GraphPad Software, Inc.) to obtain IC50 values for each treated compound. 
To evaluate the mechanism of inhibition of fatty acid uptake by Grassofermata, we 
determined the kinetics of inhibition using 4 concentrations of C1-BODIPY-C12 (2.5 to 10.0 
μM) and 7 concentrations of Grassofermata (1.25 – 15 μM). Prior to assessing uptake, a 
BioTek Synergy Plate reader equipped with micro-injectors was used to distribute 
Grassofermata at the appropriate concentration and then the substrate C1-BODIPY-C12 was 
added at timed intervals to determine initial rates of uptake over 90 seconds. Data was 
analyzed using the enzyme kinetics module of SigmaPlot® 12.0 (Systat Software, Inc.) to 
determine the best-fit model of inhibition.
2.4 Assessment of lipotoxicity and nuclear integrity
Lipid accumulation and nuclear integrity of cells was determined after treatment of HepG2 
cells with PA (0–500 μM) conjugated with BSA (2.5:1 PA:BSA) without or with 
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Grassofermata (0–50 μM) [12,13,14] or antipsychotics (0, 50 or 100 μM) for 24 hrs. INS-1E 
cells were treated with PA and Grassofermata for 24 hrs, 96 hr after plating, as described for 
HepG2 cells. Primary hepatocytes were treated with PA and Grassofermata after 4–5 hours 
of attachment. To quantify lipid accumulation after treatment, 30μM Nile Red was added to 
each well in the dark and the plates were incubated for 30 min at 37 °C 5 % CO2. Lipid 
accumulation was then estimated as arbitrary fluorescent units (AFU) using a BioTek 
Synergy plate reader (Winooski, VT) at excitation/emission of 485/590 nm.
To assess nuclear integrity, cells were stained with 2 μl of DAPI (4′,6-diamidino-2-
phenylindole; 0.5 mg/ml), incubated for 30 minutes at 37 °C, and then AFU were measured 
at excitation/emission of 360/460 nm.
2.5 Assessment of inhibition of FA absorption in mice
To assess inhibition of fatty acid uptake in live animals, 10-week old C57BL/6 male mice 
were obtained from Jackson Laboratories 1 week prior to experimentation. Groups of 12 
mice were fasted for 12 hrs and then 300 mg/kg of Grassofermata prepared in flaxseed oil or 
flaxseed oil alone (controls) was administered by gavage. To inhibit lipoprotein lipase-
dependent systemic fatty acid uptake, mice were injected with 500 mg/kg tyloxapol in PBS 
prior to gavage by intraperitoneal injection. One hour after Grassofermata administration, 
mice were given a bolus of flaxseed oil containing 500 mg/kg of 13C-oleate. At the desired 
times after oleate administration (0.5, 2 and 6 hours), animals were sacrificed, blood was 
collected via cardiac puncture in EDTA-treated tubes, and plasma was prepared for analysis.
To assess absorption of 13C-oleate, plasma (25 μl) was extracted by modification of Folch 
[15] using nonadecanoic acid (10 μg) as an internal standard. Samples were analyzed using 
an Agilent 7890A gas chromatography (GC) unit linked to an Agilent 5975C VL MSD 
(mass selective detector) (Agilent, Palo alto, CA) using electron impact ionization. GC was 
performed using an Agilent CP7421 Select FAME column, 200 m X 275 μm X 0.25 μm. 
Samples (1μl) were injected in a splitless mode with selective ion monitoring (SIM). The 
mass selective detector was set for SIM of m/z 296 for the methyl ester of endogenous 12C 
oleate and m/z 314 for the methyl ester of 13C18:1, using 100 ms dwell time per ion.
To measure Grassofermata in plasma samples, 40 μl of acetonitrile containing 11 ng of an 
internal standard (a closely related compound analogue) was mixed with 20 μl plasma. The 
sample was mixed, 40 μl 0.1 % trifluoroacetic acid (TFA) in water was added, and the 
sample was vortexed for 5 min. The samples were then centrifuged at 13,000 rpm for 5 
minutes to remove protein and the supernatants were analyzed using LC/MS-MS. For HPLC 
analysis, two mobile phases used were -mobile phase A containing 5/95/0.1 acetonitrile/
deionized water/formic acid (vol/vol) and mobile phase B containing 95/5/0.1 (vol/vol) 
acetonitrile/deionized water/formic acid. Compounds were separated on a Phenomenex 
Gemini C18 2.1 X 50 mm, 5 μm column at 40 °C with a linear gradient at 0.35 mL/min, and 
a 5 μl injection volume. The mobile phase was held at 20 % B for 1 minute, increased 
linearly to 95 % B over 3 minutes, held at 95 % B for 2 minutes, and then re-equilibrated at 
20 % B for4 minutes. For CB5, q1 and q3 were set to 457.1 and 411.1 and for internal 
standard, q1 and q3 were set to 453.4 and 407.2. The amount of Grassofermata present in 
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the plasma was determined using a standard curve obtained using known concentrations of 
Grassofermata and the internal standard (0.09 to 3.3 ng/μl).
2.6 Statistical analysis
A minimum of 3 experiments, each assayed in triplicate, were used for statistical analysis. 
Significance of differences were compared using JMP v11 analysis software (SAS Inst., 
Inc.) using ANOVA, Student’s paired t distribution, or bivariate fit Y by X. Values were 
considered statistically significant at p<0.05.
3. Results
3.1 Inhibition of C1-BODIPY-C12 uptake in C2C12, INS-1E and human adipocytes
The initial confirmation of Grassofermata as an inhibitor of fatty acid uptake was 
determined in HepG2 and Caco-2 cells, models for hepatocytes and enterocytes ([6]; Fig. 1A 
and 1B). In the present study, we examined impact of the compound on C2C12 myocytes, 
primary human adipocytes and INS-1E pancreatic β-cells, which oxidize, store and regulate 
fatty acid metabolism, respectively. Grassofermata was effective in inhibiting the uptake of 
FA analog C1-BODIPY-C12 in C2C12 and INS-1E cells with IC50 of 10.6 and 8.3 μM 
respectively (Fig. 1C and 1D). By comparison, the IC50 was higher in human adipocytes 
(58.2 μM; Fig. 1E).
We further assessed the mechanism of Grassofermata-dependent inhibition of FA uptake 
using a standard kinetics approach employing HepG2 cells. Grassofermata was varied from 
1.25 μM to 15 μM at 4 concentrations of C1-BODIPY-C12 (2.5–10 μM). As expected, 
Grassofermata exhibited a non-competitive mechanism of inhibition (Fig. 1F).
3.2 FA uptake inhibition is specific to long- and very-long chain fatty acids
To assess the inhibitory effect of Grassofermata toward uptake of FA with different chain 
lengths, we employed BODIPY FL-C5, a medium chain FA analog and BODIPY FL-C16, a 
very long chain FA analog. Uptake of the medium chain FA-analog was not saturable 
suggesting a protein-independent, diffusional mechanism ([16]; Fig. 2A and 2B). In contrast, 
uptake of the very long chain FA-analog was saturable. Grassofermata was effective in 
inhibiting the uptake of BODIPY FL-C16 in HepG2 (Fig. 2A) and Caco-2 cells (Fig. 2B) 
with IC50 values of 17.3±2.5 μM and 13.5±1.1 μM, respectively. Grassofermata did not 
affect the transport of BODIPY FL-C5 in either cell line.
3.3 Protective effect of Grassofermata against palmitate-induced cell death
Saturated free fatty acids, particularly, PA can induce lipotoxicity and apoptotic cell death 
[17]. Therefore, we predicted Grassofermata would be protective against lipoapoptosis. 
HepG2, INS-1E and freshly isolated primary mouse hepatocytes were treated with varying 
concentrations of PA (0–500 μM) without or with Grassofermata (0–50 μM) (Fig. 3). As the 
concentration of PA increased, the accumulation of lipids increased in a dose dependent 
manner. However, when Grassofermata was added along with PA less lipid was 
accumulated. At each concentration of PA, 50 μM of Grassofermata significantly reduced 
the accumulation of lipid (Fig. 3A, 3C and 3E). At other combinations of PA and 
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Grassofermata, the results were more variable, but in general, inclusion of Grassofermata 
reduced the accumulation of lipid as expected for an inhibitor of fatty acid transport.
Excessive accumulation of lipid results in lipotoxicity and associated cellular dysfunction 
contributing to disease [17]. An indicator of cellular dysfunction is nuclear fragmentation, 
which is associated with the induction of apoptosis detected as an increase in nuclear 
staining of live cells with DAPI [18]. As the concentration of PA increases, nuclear integrity 
of the cells is comprised thus leading to an increase in DAPI staining (Fig. 3B, 3D and 3F)). 
Grassofermata reduced DAPI staining of cells in a dose dependent manner that closely 
paralleled the results obtained for lipid accumulation. This inhibition of FA import and lipid 
accumulation by the compound effectively protects cells from lipotoxic cell death.
3.4 Grassofermata prevents fatty acid absorption across the gut
To evaluate whether or not Grassofermata could prevent FA absorption, the compound was 
given to mice by oral dosing and then absorption of a labeled fatty acid ([13C18 ]-oleate) was 
measured in blood collected after 0.5, 2 and 6 hrs. As shown in Fig. 4A, a single dose of 
Grassofermata (300 mg/kg) was effective in reducing the levels of labeled oleate by 37 % 6 
hrs post-label administration. The levels of Grassofermata in plasma varied from 2.1±0.6 
ng/μl at 0.5 hrs to 3.4±0.7 ng/μl at 2hrs and then were reduced to 2.9±0.7 ng/μl at 6 hrs (Fig. 
4B). This confirms the inhibitory action of Grassofermata in vivo and its effectiveness in 
preventing the uptake of fatty acids across the intestinal epithelium.
3.5 Mechanism of action of atypical antipsychotics differs from Grassofermata
In earlier work, the atypical antipsychotics, chlorpromazine and clozapine, were identified 
as inhibitors of FA uptake in humanized yeast [8]. When tested in Caco-2 cells these drugs 
had intermediate levels of inhibition (i.e. approximately 30–50 % at 100 μM) [6,8]. Since 
hyperlipidemia and metabolic syndrome are known side effects of this family of drugs [19], 
we compared a set of related compounds for ability to inhibit FA transport by comparison 
with Grassofermata (Table 1). At best, the compounds had a modest effect in preventing 
PA-mediated lipid accumulation and nuclear fragmentation when provided at relatively high 
doses (50 and 100 μM). Neither were we able to calculate an IC50 for the compounds using 
our standard FA transport assay. Thus, the hyperlipidemia induced in patients by these 
compounds cannot be ascribed to inhibition of FA uptake. We also tested Orlistat, which 
inhibits FA absorption by inhibiting pancreatic lipase. As expected, this compound also had 
no effect on C1-BODIPY-C12 uptake.
4. Discussion
In the present study, we have assessed the activity of Grassofermata, an inhibitor of FATP2-
mediated FA uptake, in cell lines that are models for pancreas and muscle, as well as human 
adipocytes. Grassofermata was effective in inhibiting the uptake of the fluorescent FA 
analogue C1-BODIPY-C12 in INS-1E and C2C12 cells that express FATP2, but was much 
less effective against human adipocytes that express FATP1 and FATP4. This is 
advantageous since adipose tissue is a safe storage depot for fat. We hypothesize 
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Grassofermata will prevent lipotoxicity in liver, muscle and pancreas redirecting the fat to 
the adipose tissue storage depots.
Prior studies have shown that Grassofermata inhibits the uptake of long chain fatty acids as 
determined using the FA analog C1-BODIPY-C12 [6]. In the present studies, Grassofermata 
was ineffective in inhibiting the uptake of medium chain FA analog BODIPY FL-C5, which 
is imported via passive diffusion. In contrast, uptake of BODIPY FL-C16, a very long chain 
FA analogue was inhibited in a dose-dependent manner. This is in accordance with our 
earlier data that show FATP2 has a preference for the uptake of long chain fatty acid and 
activation of very long chain fatty acids [20,21]. Further, the examination Grassofermata-
dependent inhibition of FA uptake demonstrated first order kinetics that was consistent with 
non-competitive mechanism. This is reasonable given that the compound is not structurally 
related to the FA substrate of the transporter or the coenzyme A that binds the AMP site as 
required for ACSVL (very long chain acyl coA synthetase) activity [4,22].
Palmitic acid is known to induce lipid accumulation and apoptosis in hepatocytes as well as 
pancreatic β-cells [17,18]. Thus, Grassofermata was tested to assess its protective effects 
against PA. The compound was able to attenuate lipid accumulation and associated nuclear 
fragmentation in HepG2 cells and primary hepatocytes in a dose dependent manner. 
Importantly, Grassofermata also protected INS-1E cells, a pancreatic β-cell line. 
Lipotoxicity of hepatocytes is hypothesized as a primary determinant of NAFLD and 
progression to NASH [2,23,24]. Pancreatic β-cell dysfunction leads to Type 2 diabetes [1]. 
Thus Grassofermata has potential utility in the prevention and/or resolution of lipotoxicity 
that would otherwise cause these diseases associated particularly with obesity.
Previously and in the current work, efficacy of Grassofermata on inhibition of fatty acid 
uptake across the intestine has been estimated by using Caco-2 cells that are a human 
epithelial colorectal adenocarcinoma cell line. Consistent with this work, we demonstrated 
using mice that Grassofermata is able to prevent the absorption of oleate uniformly labeled 
with 13C. The compound was detectible in the blood within 30 minutes of dosing by gavage 
and for up to 6 hrs indicating it is absorbed as well. Given the unique mechanisms of action, 
the FATP2 inhibitor has valuable potential to add to our arsenal of pharmaceuticals to 
prevent and treat lipotoxic disease.
Finally, we investigated whether or not atypical antipsychotic drugs (AAPs) identified in an 
early pilot screen against human FATP2 expressed in yeast [8] had activities that were 
comparable to Grassofermata. AAPs cause variable degrees of metabolic side effects 
including weight gain, dyslipidemia, insulin resistance, glucose intolerance, overt diabetes 
and, in rare cases, diabetic ketoacidosis, thus increasing the risk of cardiovascular disease 
events in schizophrenic patients prescribed these medications [25]. However, when tested 
for their ability to inhibit FA uptake using C1-BODPIY-C12 in HepG2 cells, the compounds 
were only weakly effective in inhibiting the FA uptake. They were also poorly effective in 
protecting HepG2 cells against the PA-mediated lipid accumulation. Among the compounds 
tested, only clozapine and haloperidol caused some inhibition of lipid accumulation at high 
concentrations (≤100μM) but neither inhibited the loss of nuclear integrity as determined 
using DAPI staining. Olanzapine and clozapine are associated with the highest incidence of 
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weight gain followed by risperidone and quetiapine [26]. Haloperidol does not present this 
side effect. Various studies have associated the alterations in lipid metabolism caused by 
AAP to transcriptional deregulation through SREBP1 and 2 in liver [12,13,27]. This 
information together with the present data argue against inhibition of FA transport as a 
primary mechanism of dyslipidemias and associated metabolic syndrome caused by the 
drugs.
In summary, these studies confirm the role of Grassofermata as an inhibitor of FATP2-
mediated fatty acid uptake. Grassofermata is efficacious in inhibiting the transport of 
specific classes of fatty acid, is protective against palmitate-induced lipoapoptosis, and 
inhibits fat uptake across the gut in vivo.
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• Grassofermata is a small compound inhibitor of FATP2
• Uptake inhibition is specific for long chain fatty acids
• Uptake kinetics shows low specificity for adipocytes compared to other cell 
types
• Inhibition is by a non-competitive mechanism
• Atypical antipsychotics do not inhibit FA uptake by comparison with 
Grassofermata
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Inhibition of C1-BODIPY-C12 uptake inhibition by Grassofermata in different cell lines as 
indicated (A–E). Dose response curves were fit using dose-response non-linear regression 
model in Prism 5.0 software. Values are expressed as mean ± SE for 3 experiments assayed 
in triplicates. (F) Kinetic assessment of Grassofermata inhibition of C1-BODIPY-C12 uptake 
in HepG2 cells. The inserted legend indicates the concentrations in μM of Grassofermata 
used to generate the lines in the presence of 4 concentrations of C1-BODIPY-C12 (2.5–10 
μM). Data points are the mean and the error bars indicate SD. Analysis was performed using 
SigmaPlot 12 enzyme kinetics module.
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Inhibition of uptake of BODIPY-FL-C5 and BODIPY-FL-C16 by Grassofermata in (A) 
HepG2 cells and (B) Caco-2 cells. Curves were fit using dose-response non-linear regression 
model in Prism 5.0 software. Values are expressed as mean ± SE for 3 experiments assayed 
in triplicate.
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Grassofermata prevents palmitate-induced lipid accumulation and loss of nuclear integrity. 
(A and B) HepG2 cells, (C and D) primary murine hepatocytes and (E and F) INS-1E cells. 
Lipid accumulation was evaluated using Nile Red staining and nuclear integrity was 
evaluated using DAPI staining. Bar height is the mean of the arbitrary fluorescence units 
(AFU) per 106 cells for three experiments assayed in triplicate. The data was compared 
using ANOVA (JMP 11.0) for Grassofermata versus PA. Levels not connected by the same 
letter are significantly different at p<0.05.
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Inhibition of fatty acid absorption by Grassofermata in mice. Plasma levels of (A) 13C-oleate 
and (B) Grassofermata. Bar height indicates the mean for 10–12 mice ± SE. The data was 
compared using ANOVA (JMP 11.0) for control versus Grassofermata at different time 
points.
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Table 1
Inhibition of lipid accumulation and apoptosis by antipsychotics and orlistat. No compound (black); 50μM 
(gray); and 100μM (white) compound. Refer to Fig. 3A and 3B for Grassofermata data. Levels not connected 
by the same letter are significantly different at p<0.05.
Name of compound (Type of compound/ 
Chemical class1)
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Name of compound (Type of compound/ 
Chemical class1)
Lipid Accumulation DAPI staining
Risperidone (Atypical/ Benzisoxazoles)
Haloperidol (Typical/ Butyrophenones)
Orlistat (Pancreatic lipase inhibitor)
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